Neurolixis Inc. has been awarded a 1M$ research grant by the British charity, Parkinson's UK to advance development of NLX-112, a promising Phase 2-ready candidate for treatment of levodopa-induced dyskinesia (LID). NLX-112 is an exceptionally-selective and efficacious serotonin 5-HT1A receptor agonist with considerable potential for treatment of this indication.

Read the full announcement on the Parkinson's UK web site.

Image result for parkinson uk